3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
18
Nivolumab
7
Cyclophosphamide
6
fludarabine
5
Docetaxel
4
atezolizumab
3
Specimen Handling
3
Paclitaxel
3
Ipilimumab
3
Gemcitabine
3
Drug Therapy
3
Carboplatin
3
Blood Specimen Collection
3
ulixertinib
2
poly ICLC
2
fludarabine phosphate
2
durvalumab
2
Standard of Care
2
Radiotherapy
2
Radiation
2
Observation
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Filgrastim
2
Biopsy
2
zimberelimab
1
veliparib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
High-Intensity Focused Ultrasound Ablation
×
Dermatologic
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled